---
title: "GSK’s New CEO Boosts Confidence, Shares Rise"
summary: "GSK's shares have climbed back to about £20 after 25 years, thanks to fresh leadership that has shaken off a long history of missed targets and overpromised growth. Emma Walmsley spun off the consumer arm, cut the dividend, and invested heavily in research. New boss Luke Miels keeps the bullish tone, pledging to hit a £40bn-plus revenue goal by 2031. Investors are finally seeing signs of real change."
section: "Business"
category: "Medical Research News"
imageUrl: "https://media.guim.co.uk/df7c982cc4054ee4e217ce2ecf65e6ba2ed53a51/260_0_2798_2240/500.jpg"
publishedAt: "2026-02-04T18:20:17Z"
guardianId: "business/nils-pratley-on-finance/2026/feb/04/gsk-take-two-the-bullish-tone-at-the-top-is-finally-more-convincing"
---

GSK's shares have climbed back to about £20 after 25 years, thanks to fresh leadership that has shaken off a long history of missed targets and overpromised growth. Emma Walmsley spun off the consumer arm, cut the dividend, and invested heavily in research. New boss Luke Miels keeps the bullish tone, pledging to hit a £40bn-plus revenue goal by 2031. Investors are finally seeing signs of real change.
